ios H1
Alternative Names: ios-H1Latest Information Update: 28 Sep 2024
At a glance
- Originator ImmunOs Therapeutics
- Class Antineoplastics; Immunotherapies; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Solid-tumours in Switzerland (Parenteral)
- 25 Aug 2020 ios H1 is available for licensing as of 25 Aug 2020. http://www.immunostherapeutics.com/
- 25 Aug 2020 Preclinical trials in Solid tumours in Switzerland (Parenteral) (ImmunOs Therapeutics pipeline, August 2020)